Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPY001-001 SAD and MAD Study in Healthy Participants
NCT06448247Phase 1Completed
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of SPY001 in inflammatory bowel disease (IBD) (8 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Treatment Emergent Adverse Events up to 64 weeks. Started Jun 2024; status: completed.
02
Drugs
SPY001
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06448247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448247.